Insilico Medicine Receives USD 5 Million from Menarini
Insilico received an additional $5 million milestone from Menarini following first-in-patient dosing in a Phase I trial of MEN2501, a generative AI-designed KIF18A inhibitor for chromosomally unstable solid tumours.
Generative AI Engine | 05/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy